Home › Research › Drug development
Etiology, risk factors, treatments and current status of Alzheimer's disease in Mexico
Gómez-Virgilio L, Reyes-Gutiérrez GS, Silva-Lucero MD, López-Toledo G, Cárdenas-Aguayo MD.. Gaceta medica de Mexico, 2022-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease is a neurodegenerative disorder whose etiology continues to be discussed, to the point that there are different hypotheses that seek to clarify it, in addition to the fact that, given its multifactorial nature, there are different risk factors associated with its development. As regards diagnosis, advances in molecule detection techniques at femtomolar scales have allowed to distinguish between healthy and diseased subjects at relatively early stages, although there is still much to be done. Aducanumab is a monoclonal antibody targeted against Aβ, whose marketing approval by the Food and Drug Administration has been questioned by the international medical community, given the controversial results in clinical trials.
What this study adds
Evidence grade: Low
This paper states that Alzheimer's etiology is still debated and that advances in molecule detection techniques now allow distinguishing healthy from diseased subjects at relatively early stages, though much remains to be done. It notes that aducanumab's marketing approval was questioned by the international medical community given controversial clinical trial results.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gómez-Virgilio, L., Reyes-Gutiérrez, G. S., Silva-Lucero, M. D., López-Toledo, G., & Cárdenas-Aguayo, M. D. (2022). Etiology, risk factors, treatments and current status of Alzheimer's disease in Mexico. Gaceta medica de Mexico. https://doi.org/10.24875/gmm.m22000681
Vancouver
Gómez-Virgilio L, Reyes-Gutiérrez GS, Silva-Lucero MD, López-Toledo G, Cárdenas-Aguayo MD. Etiology, risk factors, treatments and current status of Alzheimer's disease in Mexico. Gaceta medica de Mexico. 2022. doi:10.24875/gmm.m22000681. PMID: 36256566.
BibTeX
@article{gomezvirgilio2022-36256566,
author = {Gómez-Virgilio, L. and Reyes-Gutiérrez, G. S. and Silva-Lucero, M. D. and López-Toledo, G. and Cárdenas-Aguayo, M. D.},
title = {{Etiology, risk factors, treatments and current status of Alzheimer's disease in Mexico}},
journal = {Gaceta medica de Mexico},
year = {2022},
doi = {10.24875/gmm.m22000681},
pmid = {36256566},
url = {https://doi.org/10.24875/gmm.m22000681}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- As regards diagnosis, advances in molecule detection techniques at femtomolar scales have allowed to distinguish between healthy and diseased subjects at relatively early stages, although there is still much to be done.
- Aducanumab is a monoclonal antibody targeted against Aβ, whose marketing approval by the Food and Drug Administration has been questioned by the international medical community, given the controversial results in clinical trials.
- Approval of this antibody as a disease-modifying treatment for Alzheimer's disease opens the door to continue using this type of treatments, but with different therapeutic targets, such as, for example, tau protein.
- Finally, given the population tendency towards longevity, conditions such as Alzheimer's disease are gaining epidemiological importance, which is why it is imperative to analyze and link what is being done in the social, familiar, clinical and research fields and, most importantly, to find those areas of opportunity for the benefit of the patient.
Why it matters
This paper states that Alzheimer's etiology is still debated and that advances in molecule detection techniques now allow distinguishing healthy from diseased subjects at relatively early stages, though much remains to be done. It notes that aducanumab's marketing approval was questioned by the international medical community given controversial clinical trial results.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Gaceta medica de Mexico) |
| Journal's citation record | 0 / 4 | Gaceta Médica de México: journal h-index 21 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 1 / 6 | Cited 0.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author María del Carmen Cárdenas‐Aguayo: h-index 16 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidad Nacional Autónoma de México: institution h-index 668 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36256566) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.24875/gmm.m22000681
- PubMed: 36256566
- Original source →
- Free full text: Gaceta Médica de México →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development from nearby years
Also in Drug development
104 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.